J&J builds case for earlier Tecvayli use in multiple myeloma Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma.

#JohnsonandJohnson has added another piece to the #data behind its effort to move #Tecvayli into #earlierline therapy for #multiplemyeloma, including the first relapse setting.